Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07505199
PHASE1

Safety and Efficacy of FAP iCDC in Ischemic Cardiomyopathy

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

View on ClinicalTrials.gov

Summary

This study aims to evaluate the safety and efficacy of fibroblast activation protein (FAP)-targeted autologous immunosuppressive chimeric antigen receptor dendritic cell (iCDC) therapy in patients with ischemic cardiomyopathy, and to explore its potential as a novel therapeutic strategy for this disease.

Official title: Safety and Efficacy of FAP-Targeted Immunosuppressive CAR-DC in the Treatment of Ischemic Cardiomyopathy

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2026-05-21

Completion Date

2029-04-01

Last Updated

2026-07-02

Healthy Volunteers

No

Interventions

BIOLOGICAL

autologus FAP-targeted immunosuppressive CAR-DCs (iCDC)

Each subject receives FAP-targeted immunosuppressive CAR-DCs by intravenous infusion after enrollment.

OTHER

Standard medical treatment

Participants receive standard medical treatment for ischemic cardiomyopathy according to current clinical practice and guideline-directed medical therapy. No iCDC therapy is administered in this arm.

Locations (1)

Second Affiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang / 浙江, China